Harnessing Indication-Specific Data on Biosimilars

EP: 1.Utilizing Recently Approved Biosimilars in Clinical Practice

EP: 2.Transitioning to Biosimilars: Considerations for Providers and Payers

EP: 3.Navigating Challenges Associated with Biosimilars Across Various Disease States

EP: 4.Provider Acceptance Driving Confidence in Biosimilar Therapy

EP: 5.Decision-Making Process Surrounding Biosimilar Implementation

EP: 6.Biosimilar Administration Considerations Impacting Patient Experience

EP: 7.Initiating Biosimilar Treatment in Patients Without Previous Reference Biologic Experience

EP: 8.Switching Patients from Reference Product to Biosimilar

EP: 9.Defining Interchangeability and Switching in Biologics

EP: 10.Evolution of Auto-Substitution in Biosimilar Landscape

EP: 11.An Overview of Biosimilar Extrapolation During FDA Approval

Now Viewing

EP: 12.Harnessing Indication-Specific Data on Biosimilars

EP: 13.Cost Savings Related to Biosimilars

EP: 14.Payers and PBMs Impacted by Biosimilar Integration

EP: 15.Payer Support Driving Lowering of Biosimilar-Related Health Care Costs

EP: 16.Patient Conversations: Managing Patient Expectations Regarding Biosimilars

EP: 17.Key Points of Emphasis Regarding Biosimilar Integration

This is a video synopsis/summary of a panel discussion involving Ryan Haumschild, PharmD, MS, MBA; Alice B. Gottlieb, MD, PhD; Bincy Abraham, MD, MS; Jamie T. Brogan, APRN; and Vibeke Strand, MD.

Haumschild asks Abraham to reemphasize the value of indication-specific data in gastroenterology for biosimilars. Abraham says indication-specific data are highly valued because gastroenterology uses much higher and different dosing schedules than other specialties. Seeing data with the doses used specifically in inflammatory bowel disease increases confidence in recommending a switch vs a biosimilar lacking those data.

Gottlieb agrees that indication-specific data are important in dermatology given different dosing and patient factors in psoriasis vs rheumatoid arthritis.

They discussed how differences like citrate formulation affect patient preference and tolerability. The variations between biosimilars must be considered to choose optimal products. Indication-specific data provide confidence for providers when they are selecting among multiple biosimilar options.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.